olsalazine

Brand: Dipentum

Prototype: mesalamine
Drug Class: aminosalicylate (5-ASA dimer prodrug)
Drug Family: GI agent
Subclass: colonic 5-ASA prodrug
Organ Systems: gastrointestinal

Mechanism of Action

Dimer of two 5-ASA molecules linked by an azo bond. Colonic bacteria cleave the azo bond, releasing two molecules of 5-ASA locally in the colon, where they inhibit inflammatory mediator production and mucosal inflammation.

COX and lipoxygenase pathways in colonic mucosa

Indications

  • maintenance of remission in ulcerative colitis in patients intolerant to sulfasalazine

Contraindications

  • hypersensitivity to salicylates
  • renal impairment

Adverse Effects

Common

  • diarrhea (10–20% — more frequent than other 5-ASA agents)
  • abdominal pain
  • nausea
  • headache

Serious

  • renal toxicity
  • hepatotoxicity
  • pericarditis (rare)

Pharmacokinetics (ADME)

Absorption minimal systemic absorption; acts locally
Distribution colonic
Metabolism azo bond cleaved by colonic bacteria to yield two 5-ASA molecules
Excretion fecal
Half-life ~0.9 hours (olsalazine); ~0.5–1.5 hours (5-ASA)
Onset days to weeks
Peak weeks
Duration continuous
Protein Binding >99%
Vd low

Drug Interactions

Drug / Agent Mechanism Severity
azathioprine / 6-MP TPMT inhibition by 5-ASA increases 6-MP toxicity major
warfarin 5-ASA may increase anticoagulant effect moderate

Nursing Considerations

  1. Diarrhea is the most common adverse effect and may be dose-limiting; administer in divided doses with food to reduce incidence.
  2. Monitor renal function periodically; aminosalicylates carry risk of interstitial nephritis.
  3. Educate patients this is a maintenance medication and should not be stopped without consulting the prescriber.
  4. Monitor CBC and LFTs periodically; report jaundice, fatigue, or pallor.

Clinical Pearls

  • Olsalazine produces more watery diarrhea than other aminosalicylates, likely due to colonic secretory effects of the dimer before cleavage; taking with food reduces this problem.
  • Specifically indicated for patients who cannot tolerate sulfasalazine, offering equivalent efficacy without the sulfa-related side effects.

Safety Profile

Pregnancy use-with-caution
Lactation use-with-caution
Renal Adjustment Required
Hepatic Adjustment Not required
TDM Not required

Concordance Terms

Cross-referenced clinical concepts — click any term to see all content where it appears.